3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
Thoracic
1
Gynecologic
1
Genitourinary
1
Conditions
Muscle Invasive Bladder Cancer
1
Interventions
pembrolizumab
65
Nivolumab
57
Magnetic Resonance Spectroscopy
53
enzalutamide
39
Abiraterone Acetate
37
Radiosurgery
36
Gemcitabine
35
Specimen Handling
32
Radiotherapy
32
Ipilimumab
32
Androgen Antagonists
32
Prednisone
31
apalutamide
28
Cisplatin
28
Docetaxel
27
Leuprolide
26
atezolizumab
25
Carboplatin
25
durvalumab
23
cabozantinib
22
darolutamide
20
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
19
olaparib
18
Goserelin
17
Radiation
16
Gonadotropin-Releasing Hormone
16
Biopsy
16
gallium 68 PSMA-11
15
Pluvicto
15
avelumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
vistusertib
×
Genitourinary
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled